The war in Iran is disrupting more than oil markets. It’s starting to squeeze the global pharmaceutical supply chain — and long-term care facilities, which depend heavily on daily medications for their residents, are squarely in the crosshairs.
That warning comes from a growing body of analysis published by The Hill and supply chain researchers at the Council on Foreign Relations. The short version: the Persian Gulf isn’t just an energy corridor. It’s also one of the world’s most critical transit hubs for medicines and pharmaceutical ingredients — and right now, both major pathways through it are severely disrupted.
Sea shipping in the Strait of Hormuz has fallen roughly 90% below pre-war levels. Air cargo capacity in the Gulf region has dropped by nearly 79%. Drugs and active pharmaceutical ingredients that normally move through this corridor — from India, China, and Europe toward the United States and Africa — are stuck, rerouted, or delayed.
Cold-Chain Drugs at Highest Risk
The medications most immediately threatened are cold-chain drugs: vaccines, insulin, biologics, and cancer therapies that must be kept in a tight temperature window and can’t sit in a warehouse waiting for a new shipping lane to open up.
For nursing homes, that’s a serious concern. Residents with diabetes rely on daily insulin. Residents undergoing cancer treatment need biologics. Many of those drugs move primarily by air freight — and airlines can’t just add new capacity overnight when routes are closed or rerouted.
Prashant Yadav, a global health supply chain expert at the Council on Foreign Relations, notes that cargo carriers “need a week and a half to catch up for every week that air shipments are suspended.” Delays compound. Spoilage becomes a real risk.
Price Increases Already on the Way
Beyond availability, costs are rising. A combination of rerouted flights, higher air-cargo rates, and surging insurance premiums for ships means moving medicines is more expensive everywhere. At least one supply chain logistics firm warned that consumers could “see drug costs affected within four to six weeks.”
For nursing home operators already squeezed by flat Medicaid reimbursement rates and rising operational costs, a pharmaceutical price spike is yet another hit to absorb. That pressure compounds a broader pattern of federal health spending uncertainty — with Republicans weighing additional health care cuts to fund the war effort, including potential reductions to programs that nursing homes and their residents depend on.
Most experts agree that short-term supply risks remain manageable, thanks to existing inventory buffers. But those cushions are finite. If the conflict drags on — and logistics don’t recover — supply constraints will eventually show up in nursing homes just as they do elsewhere in the health care system.
What Operators Should Watch
Facility directors and pharmacy teams should begin reviewing medication inventories, particularly for cold-chain drugs, and check in with their pharmacy partners about supply projections over the next 60 to 90 days. Contingency plans — including identifying backup suppliers or therapeutic alternatives — may not be urgent yet, but now is the time to start asking the questions.
The Iran war has already reshaped federal health budgets. It may soon reshape the medicine cabinet, too.
